Key points are not available for this paper at this time.
Purpose: To investigate the 3-months outcomes of patients who underwent intraoperative intravitreal injection of Ozurdex for proliferative diabetic retinopathy (PDR).Methods: This is a prospective randomized controlled clinical trial (ChiCTR2100043399).Seventy-one patients with PDR who had indications for surgery without intravitreal injection history within 3 months preoperatively were enrolled.Patients were randomly divided into three groups based on the medicine injected intraoperatively: Ozurdex, Conbercept, and Control group.The primary outcome is the best-corrected visual acuity (BCVA) within 3 months postoperatively.The secondary outcomes include the intraocular pressure (IOP), mean sensitivity, central retinal thickness and vessels perfusion. Results:The BCVA and the mean sensitivity improved in the three groups (F = 130.8, P 0.05). Conclusion:Compared with the other two groups, anatomical outcomes was improved significantly in Ozurdex group for DR patients.Ozurdex may help to improve the visual acuity and visual sensitivity, and there is no significant difference in the change of IOP and microvascular improvement.Clinical Trial Registration: This trial is registered with the Chinese Clinical Trial Registry (http://www.chictr.org.cn,registration number ChiCTR2100043399).
Wang et al. (Fri,) studied this question.